Literature DB >> 1534047

Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing.

M Hongo1, S Ohara, Y Hirasawa, S Abe, S Asaki, T Toyota.   

Abstract

Lansoprazole is a newly developed proton pump inhibitor. The purpose of this study was to determine whether morning or evening dosage gave better control of 24-hr intragastric pH. In this study, we examined the antisecretory effect of lansoprazole by repeated intragastric pH monitoring on four occasions in eight normal subjects and compared median 24-hr pH values and pH threshold time of pH greater than or equal to 4 between morning and evening dosing, following the administration of lansoprazole 30 mg once daily in either the morning or evening for seven days. Intragastric pH was monitored before and after seven days of treatment. Both morning and evening dosing caused a rise in the intragastric pH. Median pH for 24 hr was 4.3 and 1.6 with and without lansoprazole morning dosing and 4.6 and 2.1 for evening dosing, respectively. The pH threshold curve shifted to the right with lansoprazole treatment in either case. However, no differences were found between morning and evening dosing in terms of median 24-hr pH values or pH threshold time of pH greater than or equal to 4. These results indicate that lansoprazole can be given once daily in either the morning or evening because of its potent and long-lasting antisecretory activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534047     DOI: 10.1007/bf01300386

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  [Analysis of ambulatory 24-hour intragastric pH monitoring--comparison of the effects of cimetidine 200 mg QID and 800 mg UID].

Authors:  M Hongo; S Ohara; S Asaki; Y Goto; H Sakurada; D Shibuya; T Kimpara
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1988-03

2.  Twenty four hour intragastric acidity analysis for the future.

Authors:  R Walt
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

3.  Intragastric acidity under 28-day omeprazole treatment.

Authors:  H G Dammann; T A Walter; P Müller; B Simon
Journal:  Hepatogastroenterology       Date:  1985-08

4.  Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.

Authors:  K Lauritsen; S J Rune; P Bytzer; H Kelbaek; K G Jensen; J Rask-Madsen; F Bendtsen; J Linde; M Højlund; H H Andersen
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

5.  Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.

Authors:  J Naesdal; G Bodemar; A Walan
Journal:  Scand J Gastroenterol       Date:  1984-10       Impact factor: 2.423

6.  Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.

Authors:  P J Prichard; D Rubinstein; D B Jones; F J Dudley; R A Smallwood; W J Louis; N D Yeomans
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

7.  Reduction of twenty-four-hour gastric acidity with combination drug therapy in patients with duodenal ulcer.

Authors:  W L Peterson; C Barnett; M Feldman; C T Richardson
Journal:  Gastroenterology       Date:  1979-11       Impact factor: 22.682

8.  Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.

Authors:  H Satoh; N Inatomi; H Nagaya; I Inada; A Nohara; N Nakamura; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

9.  Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer.

Authors:  C M Bate; S P Wilkinson; G V Bradby; M C Bateson; W S Hislop; J P Crowe; C P Willoughby; E M Peers; P D Richardson
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

10.  Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers.

Authors:  J C Delchier; J P Isal; S Eriksson; J C Soule
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

View more
  13 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Appropriateness of timing of drug administration in electronic prescriptions.

Authors:  Arwa Hassan; Walter E Haefeli
Journal:  Pharm World Sci       Date:  2010-01-10

3.  Fecal clearance of alpha1-antitrypsin with lansoprazole can detect protein-losing gastropathy.

Authors:  H Takeda; S Nishise; M Furukawa; R Nagashima; H Shinzawa; T Takahashi
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

Review 4.  Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.

Authors:  Fabio Baldi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

7.  Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy.

Authors:  Miho Yamasaki; Sachiyo Funakoshi; Shohei Matsuda; Tomoko Imazu; Yoshiaki Takeda; Teruo Murakami; Yorinobu Maeda
Journal:  Eur J Clin Pharmacol       Date:  2014-05-13       Impact factor: 2.953

8.  Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.

Authors:  Kazunari Murakami; Takahisa Furuta; Takashi Ando; Takeshi Nakajima; Yoshikatsu Inui; Tadayuki Oshima; Toshihiko Tomita; Katsuhiro Mabe; Makoto Sasaki; Takanori Suganuma; Hideyuki Nomura; Kiichi Satoh; Shinichiro Hori; Syuuji Inoue; Takeshi Tomokane; Mineo Kudo; Tomoki Inaba; Susumu Take; Toshifumi Ohkusa; Shojiro Yamamoto; Shigeaki Mizuno; Toshiro Kamoshida; Kenji Amagai; Junichi Iwamoto; Jun Miwa; Masaaki Kodama; Tadayoshi Okimoto; Mototsugu Kato; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

9.  Lansoprazole reduces preoperative gastric fluid acidity and volume in children.

Authors:  K Mikawa; K Nishina; N Maekawa; M Asano; H Obara
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

Review 10.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.